Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma.
BACKGROUND
The purpose of this study was to evaluate the toxicity and to determine adequate doses of combined concurrent therapy with carboplatin/UFT and radiotherapy. This regimen was designed for use on patients with complications of renal dysfunction, ischemic heart disease, or advanced age.


METHODS
Twenty-seven eligible patients with stages II-IV squamous cell carcinomas of the head and neck were treated with concurrent chemoradiotherapy. UFT was given orally at a dose of 300 mg/day daily. Carboplatin was given intravenously once a week at a dose of AUC 3-6. Radiotherapy was delivered in single daily fractions of 1.8-2.0 Gy, to a total dose of 66-70.2 Gy.


RESULTS
Unacceptable toxicity (neutropenic fever or mucotitis) was encountered with a carboplatin dose of AUC 6 and a UFT dose of 300 mg/day.


CONCLUSIONS
Combined radiotherapy and chemotherapy with carboplatin and UFT is a safe and well-tolerated regimen.
Taguchi
Takahide
T
Department of Otorhinolaryngology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Ikeda
Yoichi
Y
Mikami
Yasukazu
Y
Kawai
Satoshi
S
Arai
Yasuhiro
Y
Mochimatsu
Idumi
I
Tsukuda
Mamoru
M
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
D005641:Tegafur; D014498:Uracil; D016190:Carboplatin